Patient costs of breast cancer endocrine therapy agents under Medicare Part D vs with generic formulations
Crossref DOI link: https://doi.org/10.1186/s40064-015-0827-8
Published Online: 2015-02-03
Published Print: 2015-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Nattinger, Ann Butler
Pezzin, Liliana E
McGinley, Emily L
Charlson, John A
Yen, Tina W F
Neuner, Joan M
License valid from 2015-02-03
Article History
Received: 15 January 2015
Accepted: 16 January 2015
First Online: 3 February 2015